These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33786583)

  • 1. Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models.
    Iannello A; Vitale N; Coma S; Arruga F; Chadburn A; Di Napoli A; Laudanna C; Allan JN; Furman RR; Pachter JA; Deaglio S; Vaisitti T
    Blood; 2021 Jun; 137(24):3378-3389. PubMed ID: 33786583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
    Bojarczuk K; Wienand K; Ryan JA; Chen L; Villalobos-Ortiz M; Mandato E; Stachura J; Letai A; Lawton LN; Chapuy B; Shipp MA
    Blood; 2019 Jan; 133(1):70-80. PubMed ID: 30322870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies.
    Faia K; White K; Murphy E; Proctor J; Pink M; Kosmider N; McGovern K; Kutok J
    PLoS One; 2018; 13(8):e0200725. PubMed ID: 30067771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).
    Patel VM; Balakrishnan K; Douglas M; Tibbitts T; Xu EY; Kutok JL; Ayers M; Sarkar A; Guerrieri R; Wierda WG; O'Brien S; Jain N; Stern HM; Gandhi V
    Leukemia; 2017 Sep; 31(9):1872-1881. PubMed ID: 28017967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
    Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
    Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
    [No Abstract]   [Full Text] [Related]  

  • 6. Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status.
    Dolnikova A; Kazantsev D; Klanova M; Pokorna E; Sovilj D; Kelemen CD; Tuskova L; Hoferkova E; Mraz M; Helman K; Curik N; Machova Polakova K; Andera L; Trneny M; Klener P
    Blood Adv; 2024 Jul; 8(13):3532-3543. PubMed ID: 38713893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.
    Horwitz SM; Koch R; Porcu P; Oki Y; Moskowitz A; Perez M; Myskowski P; Officer A; Jaffe JD; Morrow SN; Allen K; Douglas M; Stern H; Sweeney J; Kelly P; Kelly V; Aster JC; Weaver D; Foss FM; Weinstock DM
    Blood; 2018 Feb; 131(8):888-898. PubMed ID: 29233821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia.
    Emadi A; Kapadia B; Bollino D; Bhandary B; Baer MR; Niyongere S; Strovel ET; Kaizer H; Chang E; Choi EY; Ma X; Tighe KM; Carter-Cooper B; Moses BS; Civin CI; Mahurkar A; Shetty AC; Gartenhaus RB; Kamangar F; Lapidus RG
    Leukemia; 2021 Jul; 35(7):1907-1924. PubMed ID: 33199836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting EZH2 Promotes Chemosensitivity of BCL-2 Inhibitor through Suppressing PI3K and c-KIT Signaling in Acute Myeloid Leukemia.
    Yang C; Gu Y; Ge Z; Song C
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation.
    Enzenmüller S; Niedermayer A; Seyfried F; Muench V; Tews D; Rupp U; Tausch E; Groß A; Fischer-Posovszky P; Walther P; Stilgenbauer S; Kestler HA; Debatin KM; Meyer LH
    Cell Death Dis; 2024 Jul; 15(7):475. PubMed ID: 38961053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.
    Vangapandu HV; Jain N; Gandhi V
    Expert Opin Investig Drugs; 2017 May; 26(5):625-632. PubMed ID: 28388280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia.
    Lu Y; Jiang X; Li Y; Li F; Zhao M; Lin Y; Jin L; Zhuang H; Li S; Ye P; Pei R; Jin J; Jiang L
    J Transl Med; 2024 Sep; 22(1):867. PubMed ID: 39334157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
    Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.
    Flinn IW; O'Brien S; Kahl B; Patel M; Oki Y; Foss FF; Porcu P; Jones J; Burger JA; Jain N; Kelly VM; Allen K; Douglas M; Sweeney J; Kelly P; Horwitz S
    Blood; 2018 Feb; 131(8):877-887. PubMed ID: 29191916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
    Guièze R; Liu VM; Rosebrock D; Jourdain AA; Hernández-Sánchez M; Martinez Zurita A; Sun J; Ten Hacken E; Baranowski K; Thompson PA; Heo JM; Cartun Z; Aygün O; Iorgulescu JB; Zhang W; Notarangelo G; Livitz D; Li S; Davids MS; Biran A; Fernandes SM; Brown JR; Lako A; Ciantra ZB; Lawlor MA; Keskin DB; Udeshi ND; Wierda WG; Livak KJ; Letai AG; Neuberg D; Harper JW; Carr SA; Piccioni F; Ott CJ; Leshchiner I; Johannessen CM; Doench J; Mootha VK; Getz G; Wu CJ
    Cancer Cell; 2019 Oct; 36(4):369-384.e13. PubMed ID: 31543463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia.
    Richter A; Fischer E; Holz C; Schulze J; Lange S; Sekora A; Knuebel G; Henze L; Roolf C; Murua Escobar H; Junghanss C
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.
    Funk CR; Wang S; Chen KZ; Waller A; Sharma A; Edgar CL; Gupta VA; Chandrakasan S; Zoine JT; Fedanov A; Raikar SS; Koff JL; Flowers CR; Coma S; Pachter JA; Ravindranathan S; Spencer HT; Shanmugam M; Waller EK
    Blood; 2022 Jan; 139(4):523-537. PubMed ID: 35084470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.
    Eide CA; Kurtz SE; Kaempf A; Long N; Agarwal A; Tognon CE; Mori M; Druker BJ; Chang BH; Danilov AV; Tyner JW
    Leukemia; 2020 Sep; 34(9):2342-2353. PubMed ID: 32094466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.
    Bate-Eya LT; den Hartog IJ; van der Ploeg I; Schild L; Koster J; Santo EE; Westerhout EM; Versteeg R; Caron HN; Molenaar JJ; Dolman ME
    Oncotarget; 2016 May; 7(19):27946-58. PubMed ID: 27056887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.